NRAS and acute myeloid leukemia: Second, while the mutation rate of NRAS in AML in THAMP (22.9%) was comparable to the numbers reported in other studies (58–60), it was considerably different from the observed mutation rate in AML in AACR GENIE 10.0-public (11.2%) (Fig. 1F).